Epithelial damage caused by intestinal permeation enhancers is a source of debate over their safety. The medium chain fatty acid, sodium caprate (C10), causes reversible membrane perturbation at high dose levels required for efficacy in vivo, so the aim was to model it in vitro. Exposure of Caco-2 monolayers to 8.5mM C10 for 60min followed by incubation in fresh buffer led to (i) recovery in epithelial permeability (i.e. transepithelial electrical resistance (TEER) and apparent permeability coefficient (Papp) of [(14)C]-mannitol), (ii) recovery of cell viability parameters (monolayer morphology, plasma membrane potential, mitochondrial membrane potential, and intracellular calcium) and (iii) reduction in mRNA expression associated with infl...
The tripeptides, Ile-Pro-Pro (IPP) and Leu-Lys-Pro (LKP), inhibit angiotensin-converting enzyme (ACE...
For drugs with high hydrophilicity and poor membrane permeability, absorption enhancers can promote ...
The tripeptides, Ile-Pro-Pro (IPP) and Leu-Lys-Pro (LKP), inhibit angiotensin-converting enzyme (ACE...
Epithelial damage caused by intestinal permeation enhancers is a source of debate concerning safety....
Sodium caprate (C10) is an oral absorption promoter that is currently in clinical trials as a compon...
Sodium caprate (C10) is an oral absorption promoter that is currently in clinical trials as a compon...
In this work, we set out to better understand how the permeation enhancer sodium caprate (C10) influ...
Salcaprozate sodium (SNAC) and sodium caprate (C10) are two of the most advanced intestinal permeati...
Salcaprozate sodium (SNAC) and sodium caprate (C10) are two of the most advanced intestinal permeati...
Salcaprozate sodium (SNAC) and sodium caprate (C10) are two of the most advanced intestinal permeati...
Salcaprozate sodium (SNAC) and sodium caprate (C10) are two of the most advanced intestinal permeati...
A major challenge in oral drug delivery is the development of novel dosage forms to promote absorpti...
The tripeptides, Ile-Pro-Pro (IPP) and Leu-Lys-Pro (LKP), inhibit angiotensin-converting enzyme (ACE...
Octreotide is approved as a one-month injectable for treatment of acromegaly and neuroendocrine tumo...
The tripeptides, Ile-Pro-Pro (IPP) and Leu-Lys-Pro (LKP), inhibit angiotensin-converting enzyme (ACE...
The tripeptides, Ile-Pro-Pro (IPP) and Leu-Lys-Pro (LKP), inhibit angiotensin-converting enzyme (ACE...
For drugs with high hydrophilicity and poor membrane permeability, absorption enhancers can promote ...
The tripeptides, Ile-Pro-Pro (IPP) and Leu-Lys-Pro (LKP), inhibit angiotensin-converting enzyme (ACE...
Epithelial damage caused by intestinal permeation enhancers is a source of debate concerning safety....
Sodium caprate (C10) is an oral absorption promoter that is currently in clinical trials as a compon...
Sodium caprate (C10) is an oral absorption promoter that is currently in clinical trials as a compon...
In this work, we set out to better understand how the permeation enhancer sodium caprate (C10) influ...
Salcaprozate sodium (SNAC) and sodium caprate (C10) are two of the most advanced intestinal permeati...
Salcaprozate sodium (SNAC) and sodium caprate (C10) are two of the most advanced intestinal permeati...
Salcaprozate sodium (SNAC) and sodium caprate (C10) are two of the most advanced intestinal permeati...
Salcaprozate sodium (SNAC) and sodium caprate (C10) are two of the most advanced intestinal permeati...
A major challenge in oral drug delivery is the development of novel dosage forms to promote absorpti...
The tripeptides, Ile-Pro-Pro (IPP) and Leu-Lys-Pro (LKP), inhibit angiotensin-converting enzyme (ACE...
Octreotide is approved as a one-month injectable for treatment of acromegaly and neuroendocrine tumo...
The tripeptides, Ile-Pro-Pro (IPP) and Leu-Lys-Pro (LKP), inhibit angiotensin-converting enzyme (ACE...
The tripeptides, Ile-Pro-Pro (IPP) and Leu-Lys-Pro (LKP), inhibit angiotensin-converting enzyme (ACE...
For drugs with high hydrophilicity and poor membrane permeability, absorption enhancers can promote ...
The tripeptides, Ile-Pro-Pro (IPP) and Leu-Lys-Pro (LKP), inhibit angiotensin-converting enzyme (ACE...